CTIS2022-502316-36-00进行中（未招募）1 期
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR) - CV0271088
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •This trial will assess elegible adults with symptomatic oHCM (NYHA Funtional Class II or III)
排除标准
- •Adults with no symptomatic oHCM (NYHA Funtional Class II or III)
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia(VALOR) - VALOREUCTR2010-021961-61-ITSUNESIS PHARMACEUTICALS, INC.750
进行中（未招募）
1 期
A study to assess the efficacy and safety of ivacaftor in children aged 3 to 5 with Cystic Fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).Cystic FibrosisEUCTR2015-001267-39-GBVertex Pharmaceuticals Incorporated14
进行中（未招募）
1 期
A study to assess the efficacy and safety of ivacaftor in children aged 3 to 5 with Cystic Fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).MedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2015-001267-39-FRVertex Pharmaceuticals Incorporated50
进行中（未招募）
1 期
Study of vosaroxin or placebo in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemiaRelapsed or refractory acute myeloid leukemiaMedDRA version: 17.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10054296Term: Acute myeloid leukemia NOSSystem Organ Class: 100000004864EUCTR2010-021961-61-CZSunesis Pharmaceuticals, Inc.750
进行中（未招募）
1 期
Study of vosaroxin or placebo in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemiaRelapsed or refractory acute myeloid leukemiaMedDRA version: 20.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10054296Term: Acute myeloid leukemia NOSSystem Organ Class: 100000004864EUCTR2010-021961-61-DESunesis Pharmaceuticals, Inc.750